Key Stats for AbbVie Stock
- Current Price: $256.46
- Target Price (Mid): ~$360
- Street Target: ~$277
- Potential Total Return: ~40%
- Annualized IRR: ~8% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
AbbVie (ABBV) built its entire post-Humira growth story on one drug holding its ground, and this year that assumption finally got tested. A competing oral psoriasis treatment, Icotyde, launched in March aimed squarely at the market where Skyrizi dominates, and the bear case was simple: an easier-to-take pill would erode share and slow AbbVie’s most important growth engine. One quarter into that competitive launch, the opposite happened. On the second-quarter earnings call, Chief Commercial Officer Jeff Stewart said the company has “absolutely seen no degradation in any of our NBRx trends. In fact, they’ve actually grown.”
That answer matters more than any single number this quarter, because share durability is the hinge the whole thesis turns on. The stock trades around $256, near the all-time closing high it set in mid-August, so buyers here are paying up on the belief that Skyrizi and Rinvoq keep compounding. What the market still cannot see is whether that belief survives a full year of oral competition, not just one quarter of it.
Why the Oral Launch Hasn’t Dented Skyrizi
Stewart’s explanation for why the oral entrant hasn’t hurt is specific: the company’s tracking shows the new pill is pulling share from other oral drugs, not from Skyrizi, and AbbVie’s new-prescription trends have grown since the March launch. CEO Rob Michael framed it as “a market expanding competitive launch,” meaning the entrant is bringing new patients into treatment rather than splitting the existing pool. The scoreboard backs that up: Skyrizi still delivered $5.5 billion in the quarter, up 24% operationally, and Rinvoq added more than $2.5 billion, up 23.7%, both still growing above 20% deep into their life cycles.
Skyrizi offers quarterly dosing and durable skin clearance, and roughly 30% of psoriasis patients eventually develop psoriatic arthritis, where AbbVie now has five years of data. A large share of moderate-to-severe patients still are not on any advanced therapy, so the runway is about market expansion more than defending a saturated base.
See historical and forward estimates for AbbVie stock (It’s free!) >>>
The Fall Catalyst That Decides the Next Leg
The next concrete test is a U.S. approval decision expected this fall for a subcutaneous induction option for Skyrizi in Crohn’s disease. It sounds technical, but the commercial logic is direct. Stewart said the company is “planning for an acceleration of our capture rate” once it launches, because the subcutaneous route lets certain physicians avoid working across two separate reimbursement channels. He expects the ramp to show up early in 2027. In the trial, the subcutaneous regimen produced endoscopic response and remission rates far above placebo, which is the metric that drives share in inflammatory bowel disease.
Beyond that, AbbVie raised its combined peak-sales expectation for Rinvoq in vitiligo and alopecia areata to approach $2 billion, above prior guidance, with U.S. decisions coming over the next few quarters. The recently closed $10.9 billion acquisition of Apogee Therapeutics, completed September 3, adds a long-acting atopic-dermatitis antibody to that dermatology push, though it dilutes earnings until 2032 and is a next-decade bet rather than a near-term driver.
Against biotech peers, AbbVie does not screen as expensive. It trades at about 14.9 times forward EBITDA, below Gilead at 16.2 times and near Amgen at 13.1 times. For a company still compounding its two lead drugs above 20%, that multiple is part of why the sell-side sees the stock as reasonably valued even near its highs.
See how AbbVie performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $256.46
- Target Price (Mid): ~$360
- Potential Total Return: ~40%
- Annualized IRR: ~8% / year
See analysts’ growth forecasts and price targets for AbbVie stock (It’s free!) >>>
Using the mid-case, the TIKR model values AbbVie at around $360 by the end of 2030, implying roughly 40% total return and about 8% annualized. The revenue side rests on two drivers: continued share gains for Skyrizi and Rinvoq across their widening indication set, and the newer neuroscience franchises, where management targets more than $5 billion of peak sales for its oral CGRP migraine portfolio and another $5 billion-plus for its Parkinson’s portfolio. The margin driver is operating leverage, with the model’s normalized net income margin widening from about 37% in 2026 toward roughly 42% by 2030 as the costly Humira defense era fades.
The primary risk is concentration. This is still a two-drug story, and Skyrizi’s key U.S. composition-of-matter patent expires in 2033, with regulatory data protection running to 2031. The upside case is that the fall Crohn’s launch, the derm approvals, and Apogee extend the growth curve into the next decade. The downside case is that oral competition bites Skyrizi in year two, a readout disappoints, and an 8% annual return with a patent cliff in view stops justifying record prices.
Conclusion
A clean approval plus visible capture-rate acceleration in fourth-quarter and early-2027 prescription data keeps the growth-runway thesis alive and the model’s mid-case in play. A slipped approval or a stalled launch hands the bears their argument at a stock trading near its highs. The Q3 report, due in late October, is the first place that shows up.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in AbbVie?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up AbbVie, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track AbbVie alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
